Cost effectiveness of biventricular pacemakers in heart failure patients

American Journal of Cardiovascular Drugs

Volumn 6, Issue 2, 2006, Pages 129-137

  Heerey, Adrienne ^a,c   Lauer, Michael ^b   AlSolaiman, Firas ^b   Czerr, Jennifer ^b   James, Karen ^b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b LERNER RESEARCH INSTITUTE   (United States)

^c NONE   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITRIC ACID DERIVATIVE;

ADULT; ANGINA PECTORIS; ARTICLE; ARTIFICIAL HEART PACEMAKER; CARDIAC PATIENT; CARDIAC RESYNCHRONIZATION THERAPY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEALTH CARE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; SYNCOPE;

CARDIAC PACING, ARTIFICIAL; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS; VENTRICULAR FIBRILLATION;

EID: 33645230393     PISSN: 11753277     EISSN: 11753277     Source Type: Journal    
DOI: 10.2165/00129784-200606020-00007     Document Type: Article

References (26)

1. Starling R. Heart failure and transplantation. In: Topol EJ, editor. Textbook of cardiovascular medicine. Philadelphia (PA): Lippincott, Williams & Wilkins, 2002: 1807-17
2. Lloyd-Jones DM. The risk of congestive heart failure: sobering lessons from the Framingham Heart Study. Curr Cardiol Rep 2001; 3: 184-90
3. American Heart Association. Heart and stroke statistical update: economic cost of cardiovascular diseases. Dallas (TX): American Heart Association, 2002
4. McGowan B, Heerey A, Ryan M, et al. Cost of treating heart failure in an Irish teaching hospital. Ir J Med Sci 2000; 169: 241-4
5. Farwell D, Patel NR, Hall A, et al. How many people with heart failure are appropriate for biventricular resynchronization? Eur Heart J 2000; 21: 1246-50
6. Kerwin WF, Botvinick EH, O'Connell JW, et al. Ventricular contraction abnormalities in dilated cardiomyopathy: effect of biventricular pacing to correct interventricular dyssynchrony. J Am Coll Cardiol 2000; 35: 1221-7
7. Unverferth DV, Magorien RD, Moeschberger ML, et al. Factors influencing the one year mortality of dilated cardiomyopathy. Am J Cardiol 1984; 54: 147-52
8. Bradley DJ, Bradley EA, Baughman KL, et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA 2003; 289: 730-9
9. Abraham WT. Rationale and design of a randomized clinical trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with advanced heart failure: the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). J Card Fail 2000; 6: 369-80
10. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. New Engl J Med 2002; 346: 1845-53
11. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344: 873-80
12. Nichol G, Kaul P, Huszti E, et al. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med 2004; 141: 343-51
13. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: part 1. Circulation 2002; 106: 516-20
14. Lloyd-Williams F, Mair F, Shiels C, et al. Why are patients in clinical trials of heart failure not like those we see in everyday practice? J Clin Epidemiol 2003; 56: 1157-62
15. Masoudi FA, Havranek EP, Wolfe P, et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 2003; 146: 250-7
16. Blackstone EH. Statistics for the rest of us: comparing apples and oranges. J Thor Cardiovasc Surg 2002; 123: 8-15
17. Rubin D. Estimating casual effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-63
18. Brener SJ, Lytle BW, Casserly IP, et al. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation 2004; 109: 2290-5
19. Gum PA, Thamilarasan M, Watanabe J, et al. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis. JAMA 2001; 286: 1187-94
20. Bureau of Labor Statistics. Consumer price index, 2004 [online]. Available from URL: http://www.bls.gov [Accessed 2004 Sep 1]
21. Briggs AH, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397-409
22. Gold MR, Siegel JE, Russell LB, et al, editors. Cost effectiveness in health and medicine. New York: Oxford University Press, 1996
23. O'Brien BJ, Briggs AH. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res 2002; 11: 455-68
24. Mark DB. Medical economics in cardiovascular medicine. In: Topol E, editor. Textbook of cardiovascular medicine. Philadelphia (PA): Lippincott, Williams and Wilkins, 2002: 957-79
25. Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation In Cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002; 40: 111-8
26. Galbreath AD, Krasuski RA, Smith B, et al. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure. Circulation 2004; 110: 3518-26